FDA grants regular approval to pembrolizumab and lenvatinib for advanced endometrial carcinoma

Trial

MK-3475-775

Drugs

Keytruda (pembrolizumab) · Anti-PD-1 antibody, Lenvima (lenvatinib) · Multikinase inhibitor

Condition

Gynecologic